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Stroke is relatively rare in children, but can lead to signiﬁcant morbidity and mortality. Understanding that children with strokes
present diﬀerently than adults and often present with unique risk factors will optimize outcomes in children. Despite an increased
incidence of pediatric stroke, there is often a delay in diagnosis, and cases may still remain under- or misdiagnosed. Clinical
presentation will vary based on the child’s age, and children will have risk factors for stroke that are less common than in adults.
Managementstrategiesinchildrenareextrapolatedprimarilyfromadultstudies,butwithdiﬀerentconsiderationsregardingshort-
term anticoagulation and guarded recommendations regarding thrombolytics. Although most recommendations for management
are extrapolated from adult populations, they still remain useful, in conjunction with pediatric-speciﬁc considerations.
1.Background
Stroke is a neurological injury caused by the occlusion or
rupture of cerebral blood vessels. Stroke can be ischemic,
hemorrhagic, or both. Ischemic stroke is more frequently
caused by arterial occlusion, but it may also be caused by
venous occlusion of cerebral veins or sinuses. Hemorrhagic
strokeistheresultofbleedingfromarupturedcerebralartery
or from bleeding into the site of an acute ischemic stroke
(AIS).
AIS accounts for about half of all strokes in children,
in contrast to adults in whom 80–85% of all strokes are
ischemic [1, 2]. Children also have a more diverse and larger
numberofriskfactorsforstrokethatdiﬀersigniﬁcantlyfrom
adults which are predominated by hypertension, diabetes,
and atherosclerosis [3, 4].
Pediatric stroke leads to signiﬁcant morbidity and mor-
tality. Roughly 10–25% of children with a stroke will die, up
to 25% of children will have a recurrence, and up to 66% will
have persistent neurological deﬁcits or develop subsequent
seizure disorders, learning, or developmental problems [3, 5,
6]. Given the onset of impairment during childhood and the
eﬀect on quality of life for the child and family, the economic
and emotional costs to society are ampliﬁed.
Early recognition of pediatric stroke should lead to
more rapid neurological consultation, imaging, treatment,
and improved outcomes. In this article, we will review the
epidemiology, clinical presentation, diﬀerential diagnosis,
risk factors and causes, and management of pediatric stroke.
Neonatal stroke will not be discussed in this paper.
2. Epidemiology
A stroke or cerebral vascular accident (CVA) in children
is typically considered to be a rare event. The reported
incidence of combined ischemic and hemorrhagic pediatric
stroke ranges from 1.2 to 13 cases per 100,000 children under
18 years of age [1, 7–15]. However, pediatric stroke is likely
more common than we may realize since it is thought to be
frequently undiagnosed or misdiagnosed. This may be due
to a variety of factors including a low level of suspicion by
the clinician and patients who present with subtle symptoms
that mimic other diseases. This, in turn, can lead to a delay in
the diagnosis of stroke. In one report, 19 out of 45 children
with a stroke did not receive a correct diagnosis until 15
hours to 3 months after initial presentation [16]. Another
study demonstrated up to a 28-hour delay in seeking medical
attentionfromtheonsetofsymptomsanda7.2-houraverage2 Emergency Medicine International
delay after presentation before any brain imaging was done
[17]. However, the reported incidence of pediatric stroke has
more than doubled from prior decade estimates [18]. This
maybeduetoacombinationofincreasedsurvivalinchildren
with risk factors for stroke, such as congenital heart disease,
sickle cell disease, and leukemia, and increased awareness
[4, 6, 18].
Stroke is more common in boys than girls, even after
controlling for diﬀerences in frequency of causes such as
trauma. There appears to be a predominance of stroke in
black children [9]. This diﬀerence remains true even after
accounting for sickle cell disease patients with stroke [15].
3. ClinicalPresentation
There are some generalizations that can be made as to
how strokes present in children (Table 1). AIS most often
presents as a focal neurologic deﬁcit. Hemiplegia is the most
commonfocalmanifestation,occurringinupto94%ofcases
[1,10,19–21].Hemorrhagicstrokesmostcommonlypresent
as headaches or altered level of consciousness, and are more
likely to cause vomiting than in AIS [1, 10, 22]. Seizures are
common in both ischemic and hemorrhagic strokes. They
occurinupto50%ofchildrenwithstrokes,arenotrestricted
to any age group, and are not limited to any speciﬁc seizure
type [23].
There can be signiﬁcant diﬀerences in the clinical pre-
sentation based on the child’s age. The younger the child, the
more nonspeciﬁc their symptoms may be. Perinatal strokes
are more likely to initially present with focal seizures or
lethargy in the ﬁrst few days after birth [18, 24]. Although
focal neurological deﬁcits from these events may not develop
until weeks or months later, infants within the ﬁrst year of
life can still present acutely with lethargy, apnea spells, or
hypotonia [5, 17, 25]. Toddlers can also present with protean
symptoms such as deterioration of their general condition,
increasedcryingandsleepiness,irritability,feedingdiﬃculty,
vomiting, and sepsis-like symptoms with cold extremities
[26]. Older children demonstrate more speciﬁc neurological
defectssimilartoadults.Theseincludehemiparesis,language
(e.g., aphasia) and speech diﬃculties, visual deﬁcits, and
headache [10, 19, 20, 27–29]. If symptoms last less than
24 hours, they are deﬁned as a transient ischemic attack
(TIA) [30]. Deﬁcits are frequently brief and may resolve
as quickly as within one hour [18]. Older children may
even be able to report prior episodes of suspicious signs or
symptoms. Recent data suggests that 33% of children with
arterial strokes had preceding TIAs that were undiagnosed at
that time [18].
Speciﬁc types of stroke will also present diﬀerently in
each age group. For example, venous sinus thrombosis
can present in all ages with fever and lethargy, but young
infants can present with a history of decreased oral intake
or respiratory distress [31–34]. Physical examination may
reveal dilated scalp veins, eyelid swelling, or a large anterior
fontanelle whereas an older child would likely present with
more slowly progressing signs, such as vomiting, headache,
or any other signs of increased intracranial pressure [31–34].
A subarachnoid hemorrhage can also present as irritability
and a bulging fontanelle in infants, but should be sus-
pected in older children complaining of sudden acute onset
headache, neck pain, meningismus, or photophobia [35].
The clinical presentation is also useful for localizing the
lesion. The majority of pediatric ischemic strokes occur in
thedistributionofthemiddlecerebralartery,whichresultsin
hemiplegia with upper limb predominance, hemianopsia, or
dysphasia.Primarilylowerextremityweaknesswouldsuggest
anterior cerebral artery involvement whereas vertigo, ataxia,
and nystagmus are consistent with an ischemic event in
the posterior circulation [19–21, 36]. Bulbar dysfunction
and dysarthria points towards lower brainstem involvement
whereas aphasia suggests involvement of the basal ganglia,
thalamus, or cerebral hemispheres. If the hemispheres are
involved, then the eyes will look towards the lesion, rather
than away as if the brainstem were involved.
4. DifferentialDiagnosis
There are many other diseases that may mimic a stroke.
Complicated migraines can cause focal neurologic symp-
toms that typically resolve within 24 hours, and should
be considered if there is a family history of migraine
or hemiplegic migraine [10]. Focal seizures can result in
subsequent transient postictal hemiparesis (Todd’s Paresis),
but stroke should be considered if the duration of the deﬁcit
is prolonged relative to the duration of the preceding seizure.
Intracranial neoplasms should be considered, as well as
intracranial infections such as meningitis, brain abscess, and
herpes simplex encephalitis [4, 37]. Although rare, alternat-
ing hemiplegia is a possibility, especially if there is a distinct
history of episodes of hemiplegia that last rarely longer
than a day, alternate between sides, and present in a child
with progressive developmental regression [23]. Common
metabolic abnormalities like hypoglycemia can cause focal,
stroke-like deﬁcits [38]. Uncommon metabolic disorders
such as MELAS (mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke), which is inherited, can also
cause stroke-like symptoms, without an actual ischemic or
hemorrhagic event [2, 39].
5.Risk FactorsandCauses
The majority of signs and symptoms of stroke are nonspe-
ciﬁc, and can be easily attributed to other causes. One way
to avoid delays or misdiagnoses would be to identify risk
factors for stroke that would prompt more aggressive and
timely investigation. Multiple risk factors are often present in
as many as 25% of children with stroke, which means further
investigations are warranted even when one risk factor has
been identiﬁed [18, 24].
5.1. Cardiac. Cardiac disease is the most common cause
of stroke in childhood, accounting for up to a third of all
AIS [4]. In children with a cardiac repair or catheterization,
nearly 50% of strokes occur within 72 hours. Long-standing
cyanotic lesions cause polycythemia and anemia, which
both increase the risk of thromboembolism and cerebral
infarction [2]. Embolic clots can arise in children withEmergency Medicine International 3
Table 1: Clinical presentation of pediatric ischemic and hemorrhagic strokes.
Ischemic Hemorrhagic
Earley et al. 1998 [1] DeVeber et al. 2000 [18] Earley et al. 1998 [1] Meyer-Heim and
Boltshauser et al. 2003 [26]
Hemiparesis or focal CNS deﬁcit 94% 51% 21% 16%
Change in mental status 28% 88% 52%
Headache 22% 59% 76%
Seizure 16% 48% 29% 28%
Speech disorder, incl. aphasia 17% 8%
Vomiting 48%
Nausea 20%
Somnolence 12%
Visual impairment 12%
Neck pain 8%
Fever/prodrome 35–40% 35–40%
cardiomyopathies,rheumaticheartdisease,prostheticvalves,
or valvular vegetation from endocarditis [2, 24]. A patent
foramen ovale (PFO) can occur in as many as 35% of people
b e t w e e na g e s1a n d2 9y e a r s ,a n dm a ys e r v ea sap o r t a lf o r
venous embolic events to pass from the right to left side of
the heart [40].
5.2. Hematologic. Sickle cell disease (SCD) is a very common
cause of pediatric stroke, occurring in 285 cases per 100,000
aﬀected children [1]. Strokes may occur as early as 18
months of age, but most children present after ﬁve years of
age [41]. AIS is more common in the younger age group
whereashemorrhagicstrokesoccursmorefrequentlyinolder
children and adults [42]. Strokes may occur in the absence
of pain or aplastic crises [43]. Two-thirds of children with
SCD who have had previous strokes but remain untreated
will have a recurrence [44]. The exact pathophysiology is not
entirely clear, although it likely involves elements of anemia,
microvascular occlusion, stasis causing reperfusion injury
physiology, and endothelial dysfunction [45].
Prothrombotic disorders have been identiﬁed in 30 to
76% of patients experiencing arterial or venous events, and
should be suspected if there is a family history of early
onset AIS (particularly if under 55 years old), heart disease,
pulmonary embolism, or deep vein thrombosis events [24,
46–49]. Acquired prothrombotic disorders secondary to
deﬁciencies in proteins C and S may occur in children with
renal and liver disease, including nephrotic syndrome with
loss of coagulation factors [2, 50]. Protein C deﬁciency
has also been reported in children taking valproate [51].
Hemorrhagic strokes can arise from both Factor VII and
factor VIII deﬁciency [52, 53]. Iron deﬁciency anemia
h a sb e e nr e p o r t e di nc h i l d r e nw i t hb o t hA I Sa n dv e n o u s
thrombosis with no other apparent etiology [24, 54, 55].
5.3. Infection. Varicella infection within the past year can
result in basal ganglia infarction [56, 57]. HIV infection
can cause stroke secondary to HIV-induced vasculitis, vas-
culopathy with subsequent aneurysms, or hemorrhage in
the context of immune thrombocytopenia [58, 59]. More
commonly associated organisms include mycoplasma and
chlamydia, as well as enterovirus, parvovirus 19, inﬂuenza
A, coxsackie, Rocky Mountain spotted fever, or cat scratch
disease [58, 60]. Five to twelve percent of children with
bacterial meningitis, TB meningitis, and viral encephalitis
will have a stroke due to local vasculitis and thrombosis.
A history of drinking raw milk or visiting a farm may
point to a diagnosis of neurobrucellosis [61]. Head and
neck infections, such as mastoiditis or periorbital infections,
remain important causes of CVT [2, 31].
5.4. Vascular. Arteriovenous malformations (AVM) are the
most common cause of hemorrhagic stroke after infancy,
but can also cause thrombotic stroke [8, 10, 62]. AVM
may be associated with neurocutaneous syndromes such as
Osler-Weber-Rendu syndrome (i.e., hereditary hemorrhagic
telangiectasia), Sturge-Weber disease, neuroﬁbromatosis, or
von Hippel-Lindau syndrome. Moyamoya is another impor-
tantvascularcauseofchildhoodstrokeandisassociatedwith
conditions such as Down syndrome, neuroﬁbromatosis, and
sickle cell disease [24, 30].
5.5. Syndromic and Metabolic Disorders. Although rare,
children with Marfan syndrome are at risk of ischemic
neurovascular complications [63]. Children with tuberous
sclerosis have a higher risk of embolic events, and may
also have hemorrhagic strokes secondary to hypertension,
hemorrhage into a tumor, or rupture of an abnormal
vessel [39]. Homocysteinuria can cause AIS and should be
suspected in the presence of mental retardation associated
with lens dislocation and occasionally pectus excavatum
[64]. Nutritional deﬁciencies of folic acid or vitamin B12
may also cause hyperhomocysteinemia, leading to stroke [2].
There is an elevated risk for AIS secondary to thrombosis
and premature arteriosclerosis [65],thelatterofwhichisalso
caused by familial lipoprotein disorders [66–69].
5.6. Vasculitis. Cerebral vasculitis is a less common cause
of stroke in children, and is more common in children
older than 14 years of age [8]. Although idiopathic vasculitis4 Emergency Medicine International
is most often diagnosed, signs and symptoms of sys-
temic vasculitides with Kawasaki disease, Henoch-Sch¨ onlein
Purpura (HSP), polyarteritis nodosa, Takayasu’s arteritis,
juvenile rheumatoid arthritis, systemic lupus erythematosus,
inﬂammatory bowel disease, sarcoidosis, Sjogren syndrome,
or Behcet disease should be considered [37, 66, 70–74].
5.7. Oncologic. Children with cancer are at increased risk
for AIS as a result of their disease, subsequent treatment,
and susceptibility to infection. Intracranial hemorrhage
may complicate an intracranial tumor [2]. Leukemia and
lymphoma create a hypercoagulable and hyperviscous state
[75]. Treatment with L-asparaginase decreases antithrombin
levels, and may trigger venous thrombosis in leukemic chil-
dren concurrently receiving prednisone [73, 76]. Radiation
therapyforopticchiasmgliomasorothersellarorsuprasellar
region tumours can cause vasculopathies that result in
strokes which may be preceded by transient ischemic attacks
(TIAs) beginning months to years after treatment [60, 77–
79].
5.8. Trauma. Children who have experienced head and
neck trauma are at risk of developing an ischemic event
subsequent to dissection of the carotid or vertebral arteries.
This can result from direct intraoral trauma delivered by
af o r e i g no b j e c ts u c ha sap e n c i li nt h em o u t ho ra f t e r
tonsillectomy, and can also occur spontaneously [37, 66,
80–82]. Hyperextension or rotational injuries experienced
during minor head trauma, motor vehicle collisions, sports
such as wrestling, or even chiropractic manipulation can also
result in strokes [60, 83, 84]. Symptoms of traumatic arterial
dissection can be delayed by 24 hours, and the risk is greatest
within a few days of the vascular injury [62, 83].
5.9. Drugs. Drug use, both illicit and prescribed, are a
concern in the adolescent population. Cerebral infarcts
and hemorrhage have been reported in patients abusing
drugs such as amphetamines, ecstasy, cocaine, phencyclidine
(PCP), and glue sniﬃng [85]. Stimulants and heroin can
also cause vasculopathies predisposing to infarction [83].
Adolescentgirlsusingoralcontraceptivesareathigherriskof
cerebral venous thrombosis [86]. Overuse of ergot alkaloids
in the treatment of acute migraines, are also associated with
increased risk of ischemic events [87].
6. Management
The management of stroke in children is less-studied and
largely extrapolated from the adult literature with the only
randomizedcontrolledtrialsforthetreatmentofacutestroke
in children in the setting of SCD. However, generalizations
and recommendations can still be made based on what is
available and consensus statements. The emergency depart-
ment management of stroke can be categorized into general
supportive measures, diagnostic modalities, and treatment
appropriate to the type of stroke identiﬁed.
Recommended universal supportive measures include
the following: fever control, normalization of serum glucose,
and maintenance of normal oxygenation as there is no
evidence that supplemental oxygen is useful in nonhypoxic
patients. Eﬀorts should be made to ameliorate increased
intracranial pressure (ICP), treat dehydration, and correct
anemia. Control of systemic hypertension is recommended,
b u tc a u t i o ns h o u l db eu s e da sr a p i dr e d u c t i o no fb l o o d
pressure has been associated with worse neurological out-
comes and larger infarcts in adults. Some experts do allow
for mild permissive hypertension. There is no evidence
to support prophylactic anticonvulsants without clinical
or electroencephalography (EEG) evidence of seizures in
children with AIS. However, anticonvulsants may be con-
sidered in children with hemorrhagic strokes and cerebral
venous sinus thrombosis (CVST). Induced hypothermia is
not recommended outside the context of a clinical trial [88].
6.1. Imaging and Testing. Noncontrast head computed
tomography (CT) is sensitive for acute bleeding and should
be obtained emergently to exclude a hemorrhagic cause of
stroke. Despite increasingly advanced imaging techniques,
the adult literature suggests that a lumbar puncture is still
needed to rule out a subarachnoid hemorrhage (SAH) if
one is not identiﬁed on CT and clinical suspicion remains
high [89]. The sensitivity of CT in detecting SAH can
be as low as 93%, and has been shown to decrease with
time from onset of symptoms [90]. SAH can be present
despite a normal neurological examination. If a hemorrhagic
stroke is identiﬁed, magnetic resonance venography (MRV)
should follow as 10% of hemorrhages in children are due
to CVST [88]. If emergent magnetic resonance imaging
(MRI) is available, it may also be used to exclude an acute
intraparenchymal bleed or SAH. One series has suggested
that MRI is as accurate as CT for the detection of hyperacute
hemorrhage (i.e., <6h o u r s )[ 91].
Noncontrast CT is also the initial study for diagnosing
AIS. Bland infarcts appear as low-density lesions within
vascularterritories,andCVSTmaypresentaslineardensities
in the deep and cortical veins. CT imaging after an AIS is
usuallynormalwithintheﬁrst12hoursaftersymptomonset,
and MRI is a more sensitive test for early detection of an
infarction [23, 88, 92]. Magnetic resonance arteriography
(MRA)andMRVshouldalsobecarriedouttoconﬁrmvessel
patency and deﬁne the vascular anatomy. MRA will yield
further information about blood ﬂow, and MRV will more
reliably identify CVST [23].
Catheter angiography (CA) yields the most precise detail
of vascular anatomy of all imaging modalities, is superior
to MRA and computed tomography angiography (CTA) for
visualization of tertiary branches and small cerebral arteries,
and can be performed in conjunction with endovascular
therapy. It can identify signs of vasculitis or dissection, and
medium or smaller artery abnormalities, which MRA may
miss.However,CAisaninvasiveprocedurethatrelativelyfew
physicians have extensive experience performing in children.
There is a relatively low likelihood of identifying a larger
vessel abnormality with CA when MRA is negative [93].
However, CA should be strongly considered in cases with
equivocal or negative ﬁndings on MR vascular imaging or
where no other explanation for stroke is identiﬁed.
CT angiography (CTA) is another option for assessing
vascular anatomy and relative cerebral blood ﬂow. It may beEmergency Medicine International 5
Table 2: Laboratory and diagnostic testing considerations for the acute pediatric stroke patient.
Additional laboratory tests to consider Additional tests to consider
Liver function Brain MRI
ESR MRA
CRP (i) Intracranial vessels
Pregnancy (ii) Extracranial great vessels (neck)
ANA MRV
Lupus anticoagulant Diﬀusion weighted imaging (DWI)
Anticardiolipin antibody CT angiogram
Beta-2 glycoprotein-1 antibody (i) Intracranial vessels
Activated protein C resistance (ii) Extracranial great vessels (neck)
Factor V Leiden mutation Contrast transthoracic echo (TTE)
Protein S/C function Cerebral angiogram
Antithrombin III Contrast transesophageal echo (TEE)
Prothrombin gene mutation Electroencephalogram (EEG)
Homocysteine level Lumbar puncture
Methyltetrahydrofolate reductase allele (MTHFR) Holter monitoring
Fibrinogen disorder Transcranial doppler
Plasminogen activator inhibitor disorder
Factor VII/VIII elevation
Factor XII deﬁciency
Plasma amino acids/urine amino and organic acids
Serum and CSF lactate/pyruvate
Hemoglobin electrophoresis
Triglycerides/cholesterol
Lipoprotein (a)
Miscellaneous bacterial, fungal, spirochetal, parasitic,
viral, and rickettsial tests (i.e., Lyme, PPD, VDRL)
Serum and CSF varicella titers
HIV titers
Adapted from Younkin [23]a n dD e v e b e r[ 92].
usedtoidentifyarterialdissectioncausingAIS,andfacilitates
rapid assessment of vascular lesions requiring immediate
surgery. Limitations of CTA include larger radiation doses
than standard CT to facilitate the thin-slice proﬁle necessary
for high-quality CTA studies. The contrast required may also
limit the volume of contrast that can be safely administered
for subsequent, more deﬁnitive delineation by CA. MRA
may be preferable to CTA, especially if the patient will
subsequentlybeundergoinganMRI.However,CTAmaystill
be useful in patients for whom MR is contraindicated. Other
investigations to consider include ultrasound to evaluate
the extracranial carotid circulation. Since cardiac anomalies
are a signiﬁcant risk factor for stroke in children, an
ECG,chestradiograph,andtransthoracicortransesophageal
echocardiography may be useful.
There are no clearly established laboratory testing guide-
lines for the assessment of pediatric stroke. Laboratory
assessment may include a variety of nonspeciﬁc blood tests
and more speciﬁc laboratory tests looking for speciﬁc causes
of stroke such as coagulopathies, hematological disorders, or
vasculitides. Table 2 provides a suggested list of laboratory
and imaging tests to consider. One should also keep in mind
that many thrombophilias are familial, and that other family
members may also be aﬀected and require evaluation.
6.2. Treatment. Once the type of stroke is identiﬁed, treat-
ment depends on the etiology. Hemorrhagic strokes may
require medical management beyond supportive measures.
Prevention of rebleeding includes correction of coagulation
defects and hematologic disorders. Recombinant factor VIIa
(rFVIIa) promotes hemostasis and has been shown to
stabilize intracerebral hematomas and reduce hemorrhage
volume. However, adult studies have not demonstrated
improved survival or functional outcome at this time [94].
Further prospective studies in adults are still needed to
determine if subsets of patients may beneﬁt from this
therapy, so it is likely too early to extrapolate this data to the
pediatric population.
Surgical management of hemorrhagic strokes is contro-
versial. There may be beneﬁt of early surgical evacuation in
patients with clinical deterioration due to mass eﬀect. Chil-
dren may warrant more aggressive intervention given their6 Emergency Medicine International
lack of cerebral atrophy which, in older adults, could poten-
tially accommodate some degree of hematoma expansion.
Although a recent prospective, multicenter trial suggested
thatsurgicalevacuationofasupratentorialintraparenchymal
hemorrhage does not improve chances of good recovery
or moderate disability beyond best medical management, a
recent meta-analysis does suggest that surgical evacuation
is associated with a reduction in the odds of being dead or
dependent[92,95].Othersurgicaloptionsincludestereotac-
tic radiosurgery, microsurgical or endovascular techniques,
and endoscopic surgical evacuation of the intracerebral
hematoma or obliteration of aneurysms and AVMs [96–
98]. Another surgical consideration is emergent splenectomy
for intraparenchymal bleeding associated with idiopathic
thrombocytopenic purpura [99].
Another goal speciﬁc to AIS management includes pre-
venting a subsequent ischemic event. Medical options in the
acute setting for prevention include anticoagulation with
low molecular weight heparin (LMWH) or unfractionated
heparin (UFH) (see Tables 3 and 4 for dosing). Although
LMWH has reproducible pharmacokinetics and requires
fewer monitoring tests, it cannot be reliably reversed with
protamine, like UFH. One recent case series, however, sug-
gests that rFVIIa may eﬀectively reverse the eﬀects of LMWH
[100].
Although the practice of initiating short-term anticoag-
ulation pending evaluation of stroke etiology in the adult
population is no longer applied, recent guidelines have
suggested that it may be prudent to start anticoagulation in
children. This is because the likelihood of a child having an
underlying condition that would beneﬁt from anticoagula-
tion (e.g., cervicocephalic arterial dissections, vasculopathy,
unrecognized cardiac disease, and coagulopathy) is higher
than in adults [88]. Anticoagulation is also often used in
children with arterial dissection, dural sinus thrombosis,
coagulation disorders, high risk of embolism, or progressive
deterioration during the initial evaluation of a new cerebral
infarction.
Long-term anticoagulation beyond the acute phase can
be provided in the form of antiplatelet agents such as
aspirin, clopidogrel, oral vitamin K antagonists like warfarin,
or weekly subcutaneous LMWH injections. However, these
measures can be initiated in consultation with the appropri-
ate specialists after the initial management and stabilization
are carried out in the emergency department setting.
Thrombolytic therapy in children with ischemic strokes
must be carried out in a guarded and judicious manner.
Published guidelines suggest that tPA may be considered
in a select group of children with CVST, but could not
makeanyfurtherrecommendations,includingwhetheradult
guidelines could be applied to adolescents who met adult
eligibility criteria [88]. Although there are case reports
and case series of IV recombinant tPA for children with
strokes, there is little else upon which to base thrombolytic
recommendations [101–104]. Despite anecdotal reports of
successful endovascular thrombolysis and IV tPA use in
children, there are other reports of high risks of hemorrhagic
complication rates in children with systemic thrombolysis
who receive IV tPA and inadequate evidence for deciding
Table 3: Protocol for using LMWH in children.
Preparation Initial treatment
dose
Initial prophylactic
dose
Reviparin, body weight-dependent dose, units/kg per 12h
<5kg 150 50
>5kg 100 30
Enoxaparin, age-dependent dose, mg/kg per 12h
<2 months old 1.5 0.75
>2 months old 1.0 0.5
Dalteparin, all-age pediatric
dose, units/kg per 24h 129 ± 43 95 ± 52
Tinzaparin, age-dependent dose, units/kg
0 to 2 months old 275
2 to 12 months old 250
1 to 5 years old 240
5 to 10 years old 200
10 to 16 years old 275
Adapted from Roach et al. [88].
which patients are the best candidates [101–103, 105, 106].
An international multicenter study, “TIPS” (thrombolysis in
pediatric stroke), is poised to begin with the goal of assessing
the safety of IV tPA within 3 hours of AIS onset, and intra-
arterial tPA within 3–6 hours of onset [107].
Management of stroke in children with sickle cell disease
deserves special mention. Ischemic strokes should be treated
with hydration and simple or partial exchange transfusion
to achieve a hemoglobin SS fraction of less than 30%
and a hemoglobin level not greater than 10g per dL to
avoid problems of hyperviscosity. Evaluation for a structural
vascular lesion in children with sickle cell disease and a
hemorrhagic stroke is reasonable. This is because there is
often an underlying aneurysm with potential for rebleeding
in adolescents with SCD who present with a SAH [108].
However, evaluation with CA to identify such aneurysms
should be deferred until after reduction of the percentage
of sickle hemoglobin because of concerns that CA might
facilitate sickling [88]. Surgical revascularization procedures
may be considered as a last resort in children with sickle
cell disease who have persisting cerebrovascular dysfunction
despite optimal medical management [88].
Rapid transfer to a tertiary pediatric center is indicated.
In situations where further information or guidance is
desired, a call to a pediatric stroke telephone consultation
service like 1-800-NOCLOTS may be useful. This is a free
service to physicians seeking advice on management of chil-
dren with stroke based on the “best available evidence.” The
service was established in 1994, and is staﬀed by pediatric
hematologists and neurologists based at the Hospital for Sick
Children in Toronto, Canada. Calling this service is not only
a means of obtaining assistance, but helps with the collection
of information for future study [109].Emergency Medicine International 7
Table 4: Protocol for systemic heparin administration and adjustment in children.
Stage aPTT (sec) Dose (units/kg) Hold (min) Rate change (%) Repeat aPTT
(I) Loading dose 75IV over 10min
(II) Initial maintenance dose
Infants < 1yo 28/h
Children > 1yo 20/h
(III) Adjustment <50 50 0 10 4h
50–59 0 0 10 4h
60–85 0 0 0 Next day
86–95 0 0 −10 4h
96–120 0 30 −10 4h
>120 0 60 −15 4h
(IV) Obtain blood for aPTT 4h after heparin load and 4h after every infusion rate change
(V) When apt values are in therapeutic range, perform daily CBC and apt measurement
Adapted from Roach et al. [88]
7. Conclusions
Strokes in children are being recognized more frequently as
diagnostic aids develop and clinician recognition improves.
However, because the incidence is still low relative to adult
strokes, and children are distinctly diﬀerent from adults,
it remains a challenge to create evidence based diagnostic
and treatment guidelines. Due to the low incidence of this
disease, future stroke research needs to be pursued with a
collaborativeeﬀortbothnationallyandinternationally.RCTs
speciﬁc to children are clearly needed to better establish
the safety and eﬃcacy of both acute and preventative
treatments. The long-awaited and highly anticipated TIPS
trial will lead the way with other studies to improve care
for children [107]. Until then, stroke should remain a
strong consideration in children with concerning signs and
symptoms and signiﬁcant risk factors, and the best available
evidence should be utilized in providing optimal medical
care.
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